Parallax Volatility Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History

Parallax Volatility Advisers’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,085	Closed	-$194K	–	2692
2023 Q2	$255K	Sell	10,085 -14,662	-59%	-$457K	﹤0.01%	1829
2023 Q1	$797K	Buy	+24,747	New	+$771K	﹤0.01%	1592
2018 Q2	–	Sell	-4,040	Closed	-$121K	–	3525
2018 Q1	$124K	Sell	4,040 -30,754	-88%	-$990K	﹤0.01%	1333
2017 Q4	$1.24M	Buy	+34,794	New	+$999K	﹤0.01%	1105

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's RVNC Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 10,085 shares — an estimated $194K sold.

Parallax Volatility Advisers first reported a position in RVNC in Q4 2017 and held it in 4 quarters. The position peaked at $1.24M in Q4 2017. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Parallax Volatility Advisers reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 10,085 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $194K.
Parallax Volatility Advisers first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
Parallax Volatility Advisers's Revance Therapeutics, Inc. position peaked at $1.24M in Q4 2017.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.